Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Margetuximab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade |
---|---|
Source | CAS 1350624-75-7 |
Species | Chimeric |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Margetuximab,MGAH-22,ERBB2, EGFR2, CD340,anti-ERBB2, EGFR2, CD340 |
Reference | PX-TA1331 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Margetuximab is an Fc-engineered human/mouse chimeric anti-HER2 monoclonal antibody of isotype IgG1 kappa . Margetuximab targets the same epitope on the HER2 extracellular domain and hass the same activity as trastuzumab. However, margetuximab has a higher affinity for both CD16A variants and a weaker one to the inhibitory CD32B Fc receptor, thereby resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and higher efficacy compared to trastuzumab. Margetuximab has been marketed under the trade name Margenza.
Related products
Reviews
Il n’y a pas encore d’avis.